DGI:Opportunistische Infektionen/Pneumocystis Pneumonie/Quellen: Difference between revisions

From Infektiopedia
imported>Bestem
(quellen)
 
imported>Bestem
No edit summary
Line 1: Line 1:
# Alanio A, Desoubeaux G, Sarfati C, et al. Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect 2011; 17(10): 1531-7.
* Alanio A, Desoubeaux G, Sarfati C, et al. Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect 2011; 17(10): 1531-7.
# Bienvenu AL, Traore K, Plekhanova I, Bouchrik M, Bossard C, Picot S. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. Int J Infect Dis 2016; 46: 11-7.
* Bienvenu AL, Traore K, Plekhanova I, Bouchrik M, Bossard C, Picot S. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. Int J Infect Dis 2016; 46: 11-7.
# Briel M, Boscacci R, Furrer H, Bucher HC. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials. BMC Infect Dis 2005; 5: 101.
* Briel M, Boscacci R, Furrer H, Bucher HC. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials. BMC Infect Dis 2005; 5: 101.
# Choi JS, Kwak SH, Kim MC, et al. Clinical impact of pneumothorax in patients with Pneumocystis jirovecii pneumonia and respiratory failure in an HIV-negative cohort. BMC Pulm Med 2022; 22(1): 7.
* Choi JS, Kwak SH, Kim MC, et al. Clinical impact of pneumothorax in patients with Pneumocystis jirovecii pneumonia and respiratory failure in an HIV-negative cohort. BMC Pulm Med 2022; 22(1): 7.
# Costiniuk CT, Fergusson DA, Doucette S, Angel JB. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/microL and virologic suppression: a systematic review. PLoS ONE 2011; 6(12): e28570.
* Costiniuk CT, Fergusson DA, Doucette S, Angel JB. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/microL and virologic suppression: a systematic review. PLoS ONE 2011; 6(12): e28570.
# Crothers K, Beard CB, Turner J, et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. Aids 2005; 19(8): 801-5.
* Crothers K, Beard CB, Turner J, et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. Aids 2005; 19(8): 801-5.
# Debourgogne A, Favreau S, Ladriere M, Bourry S, Machouart M. Characteristics of Pneumocystis pneumonia in Nancy from January 2007 to April 2011 and focus on an outbreak in nephrology. J Mycol Med 2014; 24(1): 19-24.
* Debourgogne A, Favreau S, Ladriere M, Bourry S, Machouart M. Characteristics of Pneumocystis pneumonia in Nancy from January 2007 to April 2011 and focus on an outbreak in nephrology. J Mycol Med 2014; 24(1): 19-24.
# Dettmer S, Vogel-Claussen J. Bildgebung bei respiratorischen Infektionen. Pneumologe 2021; 18: 256–67.
* Dettmer S, Vogel-Claussen J. Bildgebung bei respiratorischen Infektionen. Pneumologe 2021; 18: 256–67.
# Deutsch-Österreichische Leitlinien zur Therapie und Prophylaxe opportunistischer Infektionen bei HIV-infizierten erwachsenen Patienten. Version 2.0 ed; 2014.
* Deutsch-Österreichische Leitlinien zur Therapie und Prophylaxe opportunistischer Infektionen bei HIV-infizierten erwachsenen Patienten. Version 2.0 ed; 2014.
# Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev 2015; 4: CD006150.
* Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev 2015; 4: CD006150.
# Fisk M, Sage EK, Edwards SG, Cartledge JD, Miller RF. Outcome from treatment of Pneumocystis jirovecii pneumonia with co-trimoxazole. Int J STD AIDS 2009; 20(9): 652-3.
* Fisk M, Sage EK, Edwards SG, Cartledge JD, Miller RF. Outcome from treatment of Pneumocystis jirovecii pneumonia with co-trimoxazole. Int J STD AIDS 2009; 20(9): 652-3.
# Gits-Muselli M, White PL, Mengoli C, et al. The Fungal PCR Initiative's evaluation of in-house and commercial Pneumocystis jirovecii qPCR assays: Toward a standard for a diagnostics assay. Med Mycol 2020; 58(6): 779-88.
* Gits-Muselli M, White PL, Mengoli C, et al. The Fungal PCR Initiative's evaluation of in-house and commercial Pneumocystis jirovecii qPCR assays: Toward a standard for a diagnostics assay. Med Mycol 2020; 58(6): 779-88.
# Goto N, Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis 2011; 13(6): 551-8.
* Goto N, Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis 2011; 13(6): 551-8.
# Haase G. Pneumocystis carinii Delanoe & Delanoe (1912) has been placed in the Archiascomycetales, a class of the Ascomycota. Infect Immun 1997; 65(10): 4365-6.
* Haase G. Pneumocystis carinii Delanoe & Delanoe (1912) has been placed in the Archiascomycetales, a class of the Ascomycota. Infect Immun 1997; 65(10): 4365-6.
# Halani S, Andany N, Shah R. Pneumocystis jirovecii pneumonia prophylaxis in a 42-year-old woman on immunosuppressive therapy. CMAJ 2020; 192(43): E1306-E8.
* Halani S, Andany N, Shah R. Pneumocystis jirovecii pneumonia prophylaxis in a 42-year-old woman on immunosuppressive therapy. CMAJ 2020; 192(43): E1306-E8.
# HIV Book 2020/21. Hamburg, Germany: Medizin Fokus Verlag; 2020.
* HIV Book 2020/21. Hamburg, Germany: Medizin Fokus Verlag; 2020.
# Kaneshiro ES. Is Pneumocystis a plant? J Eukaryot Microbiol 2002; 49(5): 367-73.
* Kaneshiro ES. Is Pneumocystis a plant? J Eukaryot Microbiol 2002; 49(5): 367-73.
# Le Gal S, Damiani C, Rouille A, et al. A cluster of Pneumocystis infections among renal transplant recipients: Molecular evidence of colonized patients as potential infectious sources of Pneumocystis jiroveci. Clin Infect Dis 2012; 54(7): 62-71.
* Le Gal S, Damiani C, Rouille A, et al. A cluster of Pneumocystis infections among renal transplant recipients: Molecular evidence of colonized patients as potential infectious sources of Pneumocystis jiroveci. Clin Infect Dis 2012; 54(7): 62-71.
# Le Gal S, Pougnet L, Damiani C, et al. Pneumocystis jirovecii in the air surrounding patients with Pneumocystis pulmonary colonization. Diagn Microbiol Infect Dis 2015; 82(2): 137-42.
* Le Gal S, Pougnet L, Damiani C, et al. Pneumocystis jirovecii in the air surrounding patients with Pneumocystis pulmonary colonization. Diagn Microbiol Infect Dis 2015; 82(2): 137-42.
# Li MC, Lee NY, Lee CC, Lee HC, Chang CM, Ko WC. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect 2014; 47(1): 42-7.
* Li MC, Lee NY, Lee CC, Lee HC, Chang CM, Ko WC. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect 2014; 47(1): 42-7.
# Limper AH, Adenis A, Le T, Harrison TS. Fungal infections in HIV/AIDS. Lancet Infect Dis 2017.
* Limper AH, Adenis A, Le T, Harrison TS. Fungal infections in HIV/AIDS. Lancet Infect Dis 2017.
# Ma L, Cisse OH, Kovacs JA. A molecular window into the biology and epidemiology of Pneumocystis spp. Clin Microbiol Rev 2018; 31(3).
* Ma L, Cisse OH, Kovacs JA. A molecular window into the biology and epidemiology of Pneumocystis spp. Clin Microbiol Rev 2018; 31(3).
# Maini R, Henderson KL, Sheridan EA, et al. Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg Infect Dis 2013; 19(3): 386-92.
* Maini R, Henderson KL, Sheridan EA, et al. Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg Infect Dis 2013; 19(3): 386-92.
# Maruschke M, Riebold D, Holtfreter MC, et al. Pneumocystis pneumonia (PCP) and Pneumocystis jirovecii carriage in renal transplantation patients: a single-centre experience. Wien Klin Wochenschr 2014; 126(23-24): 762-6.
* Maruschke M, Riebold D, Holtfreter MC, et al. Pneumocystis pneumonia (PCP) and Pneumocystis jirovecii carriage in renal transplantation patients: a single-centre experience. Wien Klin Wochenschr 2014; 126(23-24): 762-6.
# Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004; 10(10): 1713-20.
* Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004; 10(10): 1713-20.
# Muhlethaler K, Bogli-Stuber K, Wasmer S, et al. Quantitative PCR to diagnose Pneumocystis pneumonia in immunocompromised non-HIV patients. Eur Respir J 2012; 39(4): 971-8.
* Muhlethaler K, Bogli-Stuber K, Wasmer S, et al. Quantitative PCR to diagnose Pneumocystis pneumonia in immunocompromised non-HIV patients. Eur Respir J 2012; 39(4): 971-8.
# Nguyen LD, Viscogliosi E, Delhaes L. The lung mycobiome: an emerging field of the human respiratory microbiome. Front Microbiol 2015; 6: 89.
* Nguyen LD, Viscogliosi E, Delhaes L. The lung mycobiome: an emerging field of the human respiratory microbiome. Front Microbiol 2015; 6: 89.
# Nunes J, Issa N, Dupuis A, Accoceberry I, Pedeboscq S. Pneumocystis in the era of prophylaxis: do the guidelines have to change? Infection 2022; 50(4): 995-1000.
* Nunes J, Issa N, Dupuis A, Accoceberry I, Pedeboscq S. Pneumocystis in the era of prophylaxis: do the guidelines have to change? Infection 2022; 50(4): 995-1000.
# Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB. Prophylactic effect of trimethoprim-sulfamethoxazole for Pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 2018; 77(5): 644-9.
* Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB. Prophylactic effect of trimethoprim-sulfamethoxazole for Pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 2018; 77(5): 644-9.
# Pegorie M, Denning DW, Welfare W. Estimating the burden of invasive and serious fungal disease in the United Kingdom. J Infect 2017; 74(1): 60-71.
* Pegorie M, Denning DW, Welfare W. Estimating the burden of invasive and serious fungal disease in the United Kingdom. J Infect 2017; 74(1): 60-71.
# Rey A, Losada C, Santillan J, et al. Pneumocystis jiroveci infection in patients with and without HIVA comparison. Rev Chilena Infectol 2015; 32(1): 77-82.
* Rey A, Losada C, Santillan J, et al. Pneumocystis jiroveci infection in patients with and without HIVA comparison. Rev Chilena Infectol 2015; 32(1): 77-82.
# Roux A, Canet E, Valade S, et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 2014; 20(9): 1490-7.
* Roux A, Canet E, Valade S, et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 2014; 20(9): 1490-7.
# Roux A, Gonzalez F, Roux M, et al. Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. Med Mal Infect 2014.
* Roux A, Gonzalez F, Roux M, et al. Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. Med Mal Infect 2014.
# Salzer HJF, Schafer G, Hoenigl M, et al. Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia. Respiration 2018.
* Salzer HJF, Schafer G, Hoenigl M, et al. Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia. Respiration 2018.
# Santos CR, de Assis AM, Luz EA, et al. Detection of Pneumocystis jirovecii by nested PCR in HIV-negative patients with pulmonary disease. Rev Iberoam Micol 2017; 34(2): 83-8.
* Santos CR, de Assis AM, Luz EA, et al. Detection of Pneumocystis jirovecii by nested PCR in HIV-negative patients with pulmonary disease. Rev Iberoam Micol 2017; 34(2): 83-8.
# Sassi M, Ripamonti C, Mueller NJ, et al. Outbreaks of Pneumocystis pneumonia in 2 renal transplant centers linked to a single strain of Pneumocystis: implications for transmission and virulence. Clin Infect Dis 2012; 54(10): 1437-44.
* Sassi M, Ripamonti C, Mueller NJ, et al. Outbreaks of Pneumocystis pneumonia in 2 renal transplant centers linked to a single strain of Pneumocystis: implications for transmission and virulence. Clin Infect Dis 2012; 54(10): 1437-44.
# Serum antibodies to the infective agents of opportunistic infections in patients with hemoblastosis, complicated with pneumonia. Zh Mikrobiol Epidemiol Immunobiol 2006; (2): 53-7.
* Serum antibodies to the infective agents of opportunistic infections in patients with hemoblastosis, complicated with pneumonia. Zh Mikrobiol Epidemiol Immunobiol 2006; (2): 53-7.
# Siegel JD, Rhinehart E, Jackson M, Chiarello L, Health Care Infection Control Practices Advisory C. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 2007; 35(10 Suppl 2): S65-164.
* Siegel JD, Rhinehart E, Jackson M, Chiarello L, Health Care Infection Control Practices Advisory C. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 2007; 35(10 Suppl 2): S65-164.
# Sokulska M, Kicia M, Wesolowska M, Hendrich AB. Pneumocystis jirovecii-from a commensal to pathogen: clinical and diagnostic review. Parasitol Res 2015; 114(10): 3577-85.
* Sokulska M, Kicia M, Wesolowska M, Hendrich AB. Pneumocystis jirovecii-from a commensal to pathogen: clinical and diagnostic review. Parasitol Res 2015; 114(10): 3577-85.
# Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002; 8(9): 891-6.
* Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002; 8(9): 891-6.
# Stringer JR, Beard CB, Miller RF. Spelling Pneumocystis jirovecii. Emerg Infect Dis 2009; 15(3): 506.
* Stringer JR, Beard CB, Miller RF. Spelling Pneumocystis jirovecii. Emerg Infect Dis 2009; 15(3): 506.
# Thomas CF, Jr., Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350(24): 2487-98.
* Thomas CF, Jr., Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350(24): 2487-98.
# Walzer PD, Evans HE, Copas AJ, Edwards SG, Grant AD, Miller RF. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis 2008; 46(4): 625-33.
* Walzer PD, Evans HE, Copas AJ, Edwards SG, Grant AD, Miller RF. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis 2008; 46(4): 625-33.
# Walzer PD. The ecology of Pneumocystis: perspectives, personal recollections, and future research opportunities. J Eukaryot Microbiol 2013; 60(6): 634-45.
* Walzer PD. The ecology of Pneumocystis: perspectives, personal recollections, and future research opportunities. J Eukaryot Microbiol 2013; 60(6): 634-45.
# Wang LI, Liang H, Ye LI, Jiang J, Liang B, Huang J. Adjunctive corticosteroids for the treatment of Pneumocystis jiroveci pneumonia in patients with HIV: A meta-analysis. Exp Ther Med 2016; 11(2): 683-7.
* Wang LI, Liang H, Ye LI, Jiang J, Liang B, Huang J. Adjunctive corticosteroids for the treatment of Pneumocystis jiroveci pneumonia in patients with HIV: A meta-analysis. Exp Ther Med 2016; 11(2): 683-7.
# Weng L, Huang X, Chen L, et al. Prognostic factors for severe Pneumocystis jiroveci pneumonia of non-HIV patients in intensive care unit: a bicentric retrospective study. BMC Infect Dis 2016; 16(1): 528.
* Weng L, Huang X, Chen L, et al. Prognostic factors for severe Pneumocystis jiroveci pneumonia of non-HIV patients in intensive care unit: a bicentric retrospective study. BMC Infect Dis 2016; 16(1): 528.
# Wörmann B, Claßen A, Cornely OA, M. vL, Sandherr M, Vehreschild J. Cotrimoxazol zur Prophylaxe und Therapie von Infektionen in der Hämatologie und Onkologie - Aktuelle Empfehlungen. DGHO; 2020.
* Wörmann B, Claßen A, Cornely OA, M. vL, Sandherr M, Vehreschild J. Cotrimoxazol zur Prophylaxe und Therapie von Infektionen in der Hämatologie und Onkologie - Aktuelle Empfehlungen. DGHO; 2020.
# Zaman MK, White DA. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia. Diagnostic and prognostic significance. Am Rev Respir Dis 1988; 137(4): 796-800.
* Zaman MK, White DA. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia. Diagnostic and prognostic significance. Am Rev Respir Dis 1988; 137(4): 796-800.
# Zou J, Qiu T, Zhou J, et al. Clinical manifestations and outcomes of renal transplantation patients With Pneumocystis jirovecii pneumonia and cytomegalovirus co-infection. Front Med (Lausanne) 2022; 9: 860644.
* Zou J, Qiu T, Zhou J, et al. Clinical manifestations and outcomes of renal transplantation patients With Pneumocystis jirovecii pneumonia and cytomegalovirus co-infection. Front Med (Lausanne) 2022; 9: 860644.

Revision as of 15:06, 1 December 2023

  • Alanio A, Desoubeaux G, Sarfati C, et al. Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect 2011; 17(10): 1531-7.
  • Bienvenu AL, Traore K, Plekhanova I, Bouchrik M, Bossard C, Picot S. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. Int J Infect Dis 2016; 46: 11-7.
  • Briel M, Boscacci R, Furrer H, Bucher HC. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials. BMC Infect Dis 2005; 5: 101.
  • Choi JS, Kwak SH, Kim MC, et al. Clinical impact of pneumothorax in patients with Pneumocystis jirovecii pneumonia and respiratory failure in an HIV-negative cohort. BMC Pulm Med 2022; 22(1): 7.
  • Costiniuk CT, Fergusson DA, Doucette S, Angel JB. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/microL and virologic suppression: a systematic review. PLoS ONE 2011; 6(12): e28570.
  • Crothers K, Beard CB, Turner J, et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. Aids 2005; 19(8): 801-5.
  • Debourgogne A, Favreau S, Ladriere M, Bourry S, Machouart M. Characteristics of Pneumocystis pneumonia in Nancy from January 2007 to April 2011 and focus on an outbreak in nephrology. J Mycol Med 2014; 24(1): 19-24.
  • Dettmer S, Vogel-Claussen J. Bildgebung bei respiratorischen Infektionen. Pneumologe 2021; 18: 256–67.
  • Deutsch-Österreichische Leitlinien zur Therapie und Prophylaxe opportunistischer Infektionen bei HIV-infizierten erwachsenen Patienten. Version 2.0 ed; 2014.
  • Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev 2015; 4: CD006150.
  • Fisk M, Sage EK, Edwards SG, Cartledge JD, Miller RF. Outcome from treatment of Pneumocystis jirovecii pneumonia with co-trimoxazole. Int J STD AIDS 2009; 20(9): 652-3.
  • Gits-Muselli M, White PL, Mengoli C, et al. The Fungal PCR Initiative's evaluation of in-house and commercial Pneumocystis jirovecii qPCR assays: Toward a standard for a diagnostics assay. Med Mycol 2020; 58(6): 779-88.
  • Goto N, Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis 2011; 13(6): 551-8.
  • Haase G. Pneumocystis carinii Delanoe & Delanoe (1912) has been placed in the Archiascomycetales, a class of the Ascomycota. Infect Immun 1997; 65(10): 4365-6.
  • Halani S, Andany N, Shah R. Pneumocystis jirovecii pneumonia prophylaxis in a 42-year-old woman on immunosuppressive therapy. CMAJ 2020; 192(43): E1306-E8.
  • HIV Book 2020/21. Hamburg, Germany: Medizin Fokus Verlag; 2020.
  • Kaneshiro ES. Is Pneumocystis a plant? J Eukaryot Microbiol 2002; 49(5): 367-73.
  • Le Gal S, Damiani C, Rouille A, et al. A cluster of Pneumocystis infections among renal transplant recipients: Molecular evidence of colonized patients as potential infectious sources of Pneumocystis jiroveci. Clin Infect Dis 2012; 54(7): 62-71.
  • Le Gal S, Pougnet L, Damiani C, et al. Pneumocystis jirovecii in the air surrounding patients with Pneumocystis pulmonary colonization. Diagn Microbiol Infect Dis 2015; 82(2): 137-42.
  • Li MC, Lee NY, Lee CC, Lee HC, Chang CM, Ko WC. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect 2014; 47(1): 42-7.
  • Limper AH, Adenis A, Le T, Harrison TS. Fungal infections in HIV/AIDS. Lancet Infect Dis 2017.
  • Ma L, Cisse OH, Kovacs JA. A molecular window into the biology and epidemiology of Pneumocystis spp. Clin Microbiol Rev 2018; 31(3).
  • Maini R, Henderson KL, Sheridan EA, et al. Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg Infect Dis 2013; 19(3): 386-92.
  • Maruschke M, Riebold D, Holtfreter MC, et al. Pneumocystis pneumonia (PCP) and Pneumocystis jirovecii carriage in renal transplantation patients: a single-centre experience. Wien Klin Wochenschr 2014; 126(23-24): 762-6.
  • Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004; 10(10): 1713-20.
  • Muhlethaler K, Bogli-Stuber K, Wasmer S, et al. Quantitative PCR to diagnose Pneumocystis pneumonia in immunocompromised non-HIV patients. Eur Respir J 2012; 39(4): 971-8.
  • Nguyen LD, Viscogliosi E, Delhaes L. The lung mycobiome: an emerging field of the human respiratory microbiome. Front Microbiol 2015; 6: 89.
  • Nunes J, Issa N, Dupuis A, Accoceberry I, Pedeboscq S. Pneumocystis in the era of prophylaxis: do the guidelines have to change? Infection 2022; 50(4): 995-1000.
  • Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB. Prophylactic effect of trimethoprim-sulfamethoxazole for Pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 2018; 77(5): 644-9.
  • Pegorie M, Denning DW, Welfare W. Estimating the burden of invasive and serious fungal disease in the United Kingdom. J Infect 2017; 74(1): 60-71.
  • Rey A, Losada C, Santillan J, et al. Pneumocystis jiroveci infection in patients with and without HIVA comparison. Rev Chilena Infectol 2015; 32(1): 77-82.
  • Roux A, Canet E, Valade S, et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 2014; 20(9): 1490-7.
  • Roux A, Gonzalez F, Roux M, et al. Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. Med Mal Infect 2014.
  • Salzer HJF, Schafer G, Hoenigl M, et al. Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia. Respiration 2018.
  • Santos CR, de Assis AM, Luz EA, et al. Detection of Pneumocystis jirovecii by nested PCR in HIV-negative patients with pulmonary disease. Rev Iberoam Micol 2017; 34(2): 83-8.
  • Sassi M, Ripamonti C, Mueller NJ, et al. Outbreaks of Pneumocystis pneumonia in 2 renal transplant centers linked to a single strain of Pneumocystis: implications for transmission and virulence. Clin Infect Dis 2012; 54(10): 1437-44.
  • Serum antibodies to the infective agents of opportunistic infections in patients with hemoblastosis, complicated with pneumonia. Zh Mikrobiol Epidemiol Immunobiol 2006; (2): 53-7.
  • Siegel JD, Rhinehart E, Jackson M, Chiarello L, Health Care Infection Control Practices Advisory C. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 2007; 35(10 Suppl 2): S65-164.
  • Sokulska M, Kicia M, Wesolowska M, Hendrich AB. Pneumocystis jirovecii-from a commensal to pathogen: clinical and diagnostic review. Parasitol Res 2015; 114(10): 3577-85.
  • Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002; 8(9): 891-6.
  • Stringer JR, Beard CB, Miller RF. Spelling Pneumocystis jirovecii. Emerg Infect Dis 2009; 15(3): 506.
  • Thomas CF, Jr., Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350(24): 2487-98.
  • Walzer PD, Evans HE, Copas AJ, Edwards SG, Grant AD, Miller RF. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis 2008; 46(4): 625-33.
  • Walzer PD. The ecology of Pneumocystis: perspectives, personal recollections, and future research opportunities. J Eukaryot Microbiol 2013; 60(6): 634-45.
  • Wang LI, Liang H, Ye LI, Jiang J, Liang B, Huang J. Adjunctive corticosteroids for the treatment of Pneumocystis jiroveci pneumonia in patients with HIV: A meta-analysis. Exp Ther Med 2016; 11(2): 683-7.
  • Weng L, Huang X, Chen L, et al. Prognostic factors for severe Pneumocystis jiroveci pneumonia of non-HIV patients in intensive care unit: a bicentric retrospective study. BMC Infect Dis 2016; 16(1): 528.
  • Wörmann B, Claßen A, Cornely OA, M. vL, Sandherr M, Vehreschild J. Cotrimoxazol zur Prophylaxe und Therapie von Infektionen in der Hämatologie und Onkologie - Aktuelle Empfehlungen. DGHO; 2020.
  • Zaman MK, White DA. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia. Diagnostic and prognostic significance. Am Rev Respir Dis 1988; 137(4): 796-800.
  • Zou J, Qiu T, Zhou J, et al. Clinical manifestations and outcomes of renal transplantation patients With Pneumocystis jirovecii pneumonia and cytomegalovirus co-infection. Front Med (Lausanne) 2022; 9: 860644.
Retrieved from "https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Opportunistische_Infektionen/Pneumocystis_Pneumonie/Quellen&oldid=9673"